Skip to main content

Table 3 Outcomes of meta-analysis in early surgery for hip fracture patients with or without antiplatelet therapy and subgroup analysis based on different drug regimens

From: Is hip fracture surgery safe for patients on antiplatelet drugs and is it necessary to delay surgery? A systematic review and meta-analysis

Outcomes

No. of trials

No. of participants

WMD or OR (95% CI)

Subtotal p value

Subtotal Heterogenicity (I2 = %)

p value between subgroup (I2 = %)

p value

Antiplatelet

Control

In-hospital mortality

 Aspirin

3

11/456

24/1128

1.11 (0.54-2.32)

0.77

0

0.81

0.59

 Clopidogrel

4

2/106

26/1242

1.17 (0.34-3.99)

0.80

0

 Clopidogrel and aspirin

1

1/34

8/619

2.31 (0.28-19.05)

0.44

Not applicable

30-day mortality

 Aspirin

2

25/371

42/756

1.22 (0.72-2.07)

0.47

89

0.64

0.56

 Clopidogrel

5

8/182

121/2070

1.20 (0.55-2.60)

0.65

0

 Clopidogrel and aspirin

1

1/34

39/619

0.45 (0.06-3.38)

0.44

Not applicable

1-year mortality

 Aspirin

2

85/371

131/756

1.91 (0.56-6.54)

0.30

90

0.55

0.43

 Clopidogrel

3

29/110

488/1534

0.90 (0.49-1.64)

0.72

41

 Clopidogrel and aspirin

1

7/34

117/619

1.11 (0.47-2.62)

0.81

Not applicable

Drop in hemoglobin

 Aspirin

4

450

879

0.12 (− 0.06-0.31)

0.18

0

0.88

0.08

 Clopidogrel

6

201

1017

0.16 (− 0.10-0.42)

0.22

0

 Clopidogrel and aspirin

1

34

619

0.00 (− 0.58-0.58)

1.00

Not applicable

Number of patients receiving blood transfusion

 Aspirin

4

253/450

465/879

1.16 (0.91-1.46)

0.23

0

0.39

0.03

 Clopidogrel

10

118/361

875/2965

1.19 (0.90-1.59)

0.23

36

 Clopidogrel and aspirin

1

24/34

337/619

2.01 (0.94-4.27)

0.07

Not applicable

Mean number of units of blood transfused

 Aspirin

5

530

1185

0.13 (− 0.13-0.40)

0.32

49

0.23

0.07

 Clopidogrel

7

250

2487

0.15 (− 0.25-0.56)

0.46

71

 Clopidogrel and aspirin

2

49

641

0.69 (0.10-1.28)

0.02

0

Length of hospital stay

 Aspirin

2

380

808

− 0.39 (− 0.83-0.06)

0.09

0

0.03

0.76

 Clopidogrel

6

257

1203

0.58 (− 0.17-1.34)

0.13

0

 Clopidogrel and aspirin

2

49

641

0.97 (− 0.40-2.34)

0.17

0

Reoperation

 Aspirin

2

3/223

3/304

1.35 (0.28-6.61)

0.71

0

0.93

0.29

 Clopidogrel

6

10/216

33/1037

1.47 (0.70-3.09)

0.31

0

Acute coronary syndrome

 Aspirin

1

8/118

5/137

1.92 (0.61-6.04)

0.26

Not applicable

0.52

0.004

 Clopidogrel

6

14/240

19/984

2.27 (1.07-4.81)

0.03

0

 Clopidogrel and aspirin

1

3/15

0/22

12.60 (0.60-264.14)

0.10

Not applicable

Cerebrovascular events

 Aspirin

2

2/140

1/159

1.64 (0.27-9.79)

0.59

39

0.76

0.53

 Clopidogrel

3

2/84

4/249

1.77 (0.35-9.04)

0.49

0

 Clopidogrel and aspirin

1

0/15

1/22

0.46 (0.02-12.12)

0.64

Not applicable

Deep venous thrombosis

 Aspirin

3

9/476

11/923

1.50 (0.58-3.84)

0.40

61

0.94

0.30

 Clopidogrel

4

2/162

14/1435

1.60 (0.45-5.74)

0.47

0

 Clopidogrel and aspirin

1

0/34

9/619

0.93 (0.05-16.33)

0.96

Not applicable

Pulmonary embolism

 Aspirin

2

2/358

4/786

1.06 (0.22-5.14)

0.95

0

0.79

0.54

 Clopidogrel

6

2/251

14/1664

1.37 (0.44-4.23)

0.59

0

 Clopidogrel and aspirin

1

0/34

2/619

3.58 (0.17-76.02)

0.41

Not applicable

Wound-related complications

 Aspirin

4

14/498

25/945

0.86 (0.44-1.69)

0.67

0

0.34

0.48

 Clopidogrel

8

14/287

35/2398

1.52 (0.75-3.09)

0.24

0

 Clopidogrel and aspirin

2

2/49

10/641

2.60 (0.49-13.74)

0.26

0

Major bleeding

 Aspirin

1

3/98

10/342

1.05 (0.28-3.89)

0.94

Not applicable

0.58

0.48

 Clopidogrel

3

5/91

13/444

1.75 (0.52-5.91)

0.37

0